Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics.

ABSTRACT: Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of early stages of Alzheimer's disease (AD) and has been approved by the European Medicines Agency. An Early Market Authorization could be submitted to the French regulatory agencies, potentially allowing for the drug's use in clinical practice in France in 2025. To guide French clinicians in administering lecanemab in a standardized way, the French Federation of Memory Clinics has developed appropriate use recommendations for lecanemab that highlight relevant questions established to ensure an optimal risk-benefit ratio. The recommendations emphasize that lecanemab treatment requires a comprehensive individualized evaluation of the risk-benefit rat

SUBMITTER: Villain N 

PROVIDER: S-EPMC12184063 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature